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Abstract
Background: We have demonstrated that vaccination with pDNA encoding cysteine proteinase Type II (CPA) and Type I
(CPB) with its unusual C-terminal extension (CTE) can partially protect BALB/c mice against cutaneous leishmanial infection.
Unfortunately, this protection is insufficient to completely control infection without booster injection. Furthermore, in
developing vaccines for leishmaniasis, it is necessary to consider a proper adjuvant and/or delivery system to promote an
antigen specific immune response. Solid lipid nanoparticles have found their way in drug delivery system development
against intracellular infections and cancer, but not Leishmania DNA vaccination. Therefore, undefined effect of cationic solid
lipid nanoparticles (cSLN) as an adjuvant in enhancing the immune response toward leishmanial antigens led us to refocus
our vaccine development projects.
Methodology/Principal Findings: Three pDNAs encoding L. major cysteine proteinase type I and II (with or without CTE)
were formulated by cSLN. BALB/c mice were immunized twice by 3-week interval, with cSLN-pcDNA-cpa/b, pcDNA-cpa/b,
cSLN-pcDNA-cpa/b
-CTE, pcDNA-cpa/b
-CTE, cSLN, cSLN-pcDNA and PBS. Mice vaccinated with cSLN-pcDNA-cpa/b
-CTE showed
significantly higher levels of parasite inhibition related to protection with specific Th1 immune response development,
compared to other groups. Parasite inhibition was determined by different techniques currently available in exploration
vacciation efficacy, i.e., flowcytometry on footpad and lymph node, footpad caliper based measurements and imaging as
well as lymph node microtitration assay. Among these techniques, lymph node flowcytometry was found to be the most
rapid, sensitive and easily reproducible method for discrimination between the efficacy of vaccination strategies.
Conclusions/Significance: This report demonstrates cSLN’s ability to boost immune response magnitude of cpa/cpb
-CTE
cocktail vaccination against leishmaniasis so that the average parasite inhibition percent could be increased significantly.
Hence, cSLNs can be considered as suitable adjuvant and/or delivery systems for designing third generation cocktail
vaccines.
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Introduction
Leishmaniasis is one of the most important vector borne
infections that can cause a spectrum of diseases, ranging from a
clinically silent process to a fatal progressive disease in human. It is
a major public health crisis in many countries including Iran
resulting in an estimated of 12 million new cases occurrence, each
year (World Health Organization website, http://www.who.int/
vaccine_research/diseases/soa_parasitic/en/index3.html). This
parasitic disease is diagnosed as three clinical forms named
cutaneous, mucocutaneous and visceral leishmaniasis. Clinical
manifestation of the disease depends on both the species involved
and the host. The tissue lesion in cutaneous form, can last for
months or years before healing. An interesting feature is that
despite the disappearance of the lesion and resistance to
reinfection, residual parasites remain in the host, probably for
a very long time, if not forever [1]. Current curative therapies for
cutaneous leishmaniasis are costly, often poorly tolerated and not
always effective. This disease is one the few parasitic diseases
likely to be controllable with vaccination [2]. Generally;
vaccination is largely protein-based and requires direct admin-
istration of dead or attenuated parasite, recombinant proteins, or
virus-like particles. For targets resembling intracellular pathogens
like Leishmania species, such vaccines generate incomplete
immune responses and fail to induce protective affects as usually
generate only antibody-mediated (humoral) immune responses
and often require periodic booster injections [2,3]. However,
cell-mediated immune responses are required for clearance of
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cells that kill infected cells. Currently, only attenuated live
organism vaccines generate significant cell-mediated immune
responses, but these are associated with certain safety concerns
and can be difficult to manufacture consistently [2,3]. DNA
vaccination offers an attractive alternative to traditional non
replicating vaccine strategies. Intracellular production of antigens
from delivered DNAs can result in both humoral and cellular
immune responses. DNA-based vaccines also offer practical
advantages as well, mostly because of the capability of developing
countries to cheaply and rapidly produce pDNA from bacteria.
Furthermore, it is possible to formulate several antigens from
different stages of the parasite life cycle or different subspecies as
one shot of vaccine [4]. However, despite decades of research,
safe and efficient delivery of pDNA to initiate proper immune
responses remains one of the major drawbacks in bringing DNA
vaccination into clinical trials. Synthetic particle carrier systems
are known as one of the important tools for improvement of
current performed DNA vaccines. In such approaches, pDNA is
encapsulated into, or complexed via electrostatic interaction with
a synthetic carrier, resulting in fabrication of particles with a size
ranging from nanometers (nm) to few micrometers. The pDNA
release from these particles has proven to be a very effective
delivery strategy as the passive targeting to antigen presenting
cells (APCs) by size exclusion mechanism, protection from
nuclease degradation, cellular uptake enhancement, antigen
depot formation at the injection site and controlling the release
rates of pDNA that might be important for timing immune
responses, are all likely to be occurred [5].
Lipid-based delivery systems represent one of the most
advanced drug delivery technologies to date. Different lipid-based
adjuvants are introduced and evaluated for pDNA formulation,
e.g. Solid lipid nanoparticles (SLN) [based on class I of lipids],
liposomes, Transfersomes, niosomes and virosomes [based on class
II of lipids] and Micelles, emulsions [based on class III of lipids]
[6]. In general, the common ground of these systems for
transfection is the need for cationic lipids such as 1, 2-dioleoyl-3-
trimethylammonium (DOTAP) to facilitate pDNA binding. A
neutral helper lipid such as L-alpha-dioleoyl phosphatidylethanol-
amine (DOPE) or cholesterol is also required to increase the
transfection properties of the pDNA/lipid complexes. Several
authors have administered liposomes, niosomes and other lipid
based systems for pDNA delivery [6]. But despite offering a
number of technological advantages over other existing transfec-
tion reagents, SLN utility for DNA vaccination has not been
conveniently investigated in vivo. As SLN can be manufactured in
large scale and under favorable technological parameters without
the need for organic solvents and have an acceptable stability that
facilitates their manipulation for different processes such as
lyophilization and steam sterilization [7,8], they may become a
potentially valuable addition and promising alternative to the well-
established dossier of non-viral transfection agents leading by
cationic liposomes.
Leishmania express large quantities of cysteine proteinases (CP)
which are members of the papain superfamily [9]. In Leishmania
major (L. major), two most important CPs have been described. CPA
is a type II cysteine proteinase which is expressed at higher level in
amastigote stage and stationary phase promastigote. CPB is a type
I cysteine proteinase which present maximally at the amastigote
developmental stage and is encoded with an unusual C-terminal
extension [10].The presence of this highly variable CTE
differentiates Leishmanial rCPB from the other CPs in the papain
superfamily [10,11,12]. CTE can be glycosylated and partially
removed by proteolytic cleavage during processing of the enzyme
to its mature form [11]. Hence, CTE fragment is not crucial for
enzyme activity and intracellular trafficking, although it is highly
immunogenic and responsible for immune evasion and play a role
in the diversion of the host immune response [11,12]. We have
reported that antigenic rCTE of L. infantum elicitated a
predominant IgG2 response in asymptomatic dogs and in vitro
proliferation of PBMCs. Immunization with CTE also displayed
both type 1 and 2 immune signatures in experimental murine
model of L. infantum infection and therefore is not protective as a
vaccine candidate [13].
Furthermore, we had demonstrated that the cpa/cpb cocktail is
more protective against cutaneous leishmanial infection than the
separate forms [14]. Therefore, there was still a need to study the
effect of CTE deletion in this cocktail vaccine against L. major.
Despite the proven antigenicity and immugenicity of these DNA
vaccine candidates, the largest drawback of this kind of
vaccination is the obscurity in intracellular delivery of pDNA that
causes low levels of gene expression (transfection) which in turn
limits the resulting immune responses [15]. Therefore, pDNA
must use with a proper and safe formulation in order to coordinate
innate and adaptive immune responses and generate strong
immunity.
Recently, several immunoadjuvants like BCG, G-CSF and
CpG-ODN and also various delivery systems like PLGA
microspheres and liposomes have been used to potentiate the
immune responses against Leishmania antigens [16].
Herein, we used cationic solid-lipid nanoparticle (cSLN) as a
non viral transfection agent for delivery of the cocktail DNA
vaccine. In our previous studies, cSLN formulation as a delivery
system have revealed comparable efficiency/cytotoxicity ratio to
linear PEI-25 kDa-pDNAs polyplexes, protected cpa, cpb-
CTE and
cpb genes from extracellular enzymatic degradation and also
exhibited considerable low cytotoxicity [17]. In this study, these
characterized formulations of cocktail vaccine candidates were
evaluated for their immune induction potential in BALB/c mice as
sucesptible animal model.
Author Summary
Cutaneous leishmaniasis (CL) is the most common form of
leishmaniasis with an annual incidence of approximately 2
million cases and is endemic in 88 countries, including Iran.
CL’s continued spread, along with rather ineffectual
treatments and drug-resistant variants emergence has
increased the need for advanced preventive strategies. We
studied Type II cysteine proteinase (CPA) and Type I (CPB)
with its C-terminal extension (CTE) as cocktail DNA vaccine
against murine and canine leishmaniasis. However, adju-
vants’ success in enhancing immune responses to selected
antigens led us to refocus our vaccine development
programs. Herein, we discuss cationic solid lipid nanopar-
ticles’ (cSLN) ability to improve vaccine-induced protective
efficacy against CL and subsequent lesion size and parasite
load reduction in BALB/c mice. For this work, we evaluated
five different conventional as well as novel parasite
detection techniques, i.e., footpad imaging, footpad flow-
cytometry and lymph node flowcytometry for disease
progression assessments. Vaccination with cSLN-cpa/cpb
-CTE
formulation showed highest parasite inhibition at 3-month
post vaccination. Immunized mice showed reduced IL-5
level and significant IFN-a ˜ increase, compared to control
groups. We think our study represents a potential future
and a major step forward in vaccine development against
leishmaniasis.
cSLN-cps as a Vaccine Formulation against L. major
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Materials and chemicals
All solutions were prepared using MilliQ
TM ultrapure (Milli-Q-
System, Millipore, Molsheim, France) and apyrogenic water to
avoid surface-active impurities. Cetyl palmitate, tween 80 and
cholesterol were purchased from Merck (Darmstadt, Germany). N-
[1-(2,3-Dioleoyloxy) propyl]-N,N,N trimethylammonium chloride
(DOTAP), Sodium dodecyl sulfate (SDS) were purchased from
Sigma–Aldrich (Deisenhofen, Germany) The materials applied for
PCR, enzymatic digestion and agarose gel electrophoresis were
acquired from Roche Applied Sciences (Mannheim, Germany).
Cell culture reagents including Fetal Calf Sera (FCS), M199
medium, HEPES, L-glutamine, adenosine, hemin, gentamicin,
and RPMI were sourced from GIBCO (Gibco, Life Technologies
GmbH, Karlsruhe, Germany) and Sigma (Germany) respectively.
cSolid lipid nanoparticles preparation
The cSLN suspension was produced by a technique previously
described by Doroud et al. [17]. Briefly, desired amount of
DOTAP (0.4% w/v) was dissolved in hot aqueous phase which
was then added to the melted cetyl palmitate and cholesterol (5.1%
w/v) phase containing tween 80 as a nonionic surfactant at 3.2:1
molar ratio. Emulsification was carried out by stirring the mixture
at 2000 rpm by a mechanical stirrer (IKAH, Germany) for 10 min
at 90uC. Samples were then homogenized using a high shear
homogenizer (IKAH, Germany) at 18,000 g for 15 min. cSLN
dispersion was obtained by direct cooling of hot O/W micro-
emulsion on an ice-bath while stirring at 1000 rpm. cSLNs were
washed by centrifugation (6000 g, 10 min, three times) using
100 kDa AmiconH Ultra centrifugal filters (Millipore, Schwal-
bach/Ts, Germany) to purify the suspension from the excess
amounts of surfactant. Endotoxin concentration in the cSLN
formulation was determined by limulus amoebocyte lysate (LAL)
assay (LAL Kit, Charles Riever Endosafe, T2092 CTK7, and
USA).The physicochemical stability of the formulations were
evaluated at 461uC, 2561uC at dark for 1 month at regular time
intervals via observation of any changes in suspension clarity,
particle size and zeta potential assessments.
Plasmid construction and purification
pGEM-cpa, pGEM-cpb and pGEM-cpb
-CTE were available from
our previous studies [17] and each of antigenic fragments were
subcloned into pcDNA 3.1(2) vector (Invitrogen). Plasmid DNAs
were transformed into the DH5a E. coli strain and purified by
alkaline lysis method (QIAGEN Endofree Plasmid Giga Kit) and
then confirmed by PCR and digestion (data not shown). In all
three constructs (pcDNA -cpa, pcDNA -cpb, and pcDNA –cpb
-CTE),
the cpa, cpb, and cpb
-CTE open reading frames were under control of
the CMV promoter, inserted downstream of a Kozak consensus
sequence and in frame with an initiation codon. The total
concentration and purity of pDNAs were determined by
NanoDropH ND-1000 spectrophotometer (Labtech, UK).
Expression and purification of recombinant CPA, CPB and
CPB
-CTE for ELISA and cytokine assays
Construct corresponding to pQE-cpa and pQE-cpb were
produced in fusion form with an N-terminal histidine (6XHis-
tag) for expression and purification of rCPA and rCPB, as
previously described [14]. The cpb
-CTE gene was subcloned into the
cloning site of the bacterial expression vector pET-23a expression
plasmid, downstream of the T7 promoter. The E. coli strain BL21
(DE3) was transformed with pET-cpb
-CTE and grown at 37uCi n
100 ml LB medium supplemented with 100 mg/ml ampicillin and
25 mg/ml chloramphenicol.
The culture was induced with 1 mM IPTG at an OD600 of 0.8
and grown for a further 4.5 h at 37uC. Cells were centrifuged at
8000 rpm for 20 min. Bacterial pellets were dissolved in lysis
buffer [50 mM Tris–HCl (pH=8), 100 mM NaCl and 1 mM
EDTA] and frozen overnight at 220uC. After centrifugation
(10,000 g, 15 min at 4uC) pellets were washed extensively with
washing buffer [20 mM Tris–HCl (pH 8), 20 mM NaCl and
1 mM EDTA]. Inclusion Bodies (IB) were purified by imidazole-
SDS-Zn reverse staining method. The purified recombinant
protein was concentrated by ultrafiltration using Amicon Filter
(MWCO: 10 kDa) and dialysed against PBS. Protein concentra-
tion was determined with BCA assay kit (Pierce, Rockford, USA).
Purified recombinant proteins were analyzed by SDS-PAGE and
Coomassie blue staining to assess the integrity and purity of
proteins. These proteins were recognized by previously prepared
rabbit anti-CPB antisera using western blot technique [12].
Complexation between cSLN and plasmid constructs
cSLN–pDNA complexes were prepared by adding volumes
corresponded to 650 mg of each purified pDNA (pcDNA-cpa,
pcDNA-cpb, pcDNA-cpb
-CTE) to cSLN suspension at a DO-
TAP:pDNA ratio of 6:1 (w/w) and 60 min incubation at room
temperature separately, as described before [17]. The final
formulations were named as Spa, Spb and Spb
-CTE respectively.
Complete condensation of pDNAs, complexation with cSLN and
the ability of the formulation to protect pDNAs from DNase I
digestion were analyzed as previously demonstrated by agarose gel
electrophoresis [17].
Characterization of the cSLN-pDNA formulations in vitro
Measurement of size and zeta potential. The sizes of
cSLNs and cSLN–pDNA complexes were determined by photon
correlation spectroscopy (PCS). For this purpose, the SLN in water
dispersions were diluted in the ratio of 1:100 before analysis. Both
size and zeta potential measurements were performed on a
Malvern Zetasizer 3000 (Malvern Instruments, Worcestershire,
UK). The analysis was performed on each sample immediately
after preparation of the cSLNS and 2 hrs after preparing the
cSLN-pDNA complex in milli Q water.
Gel retardation analysis. Gel retardation assay was applied
to determine complex formation between pDNA (5 mg) and cSLNs
(DOTAP different weight ratios). For this purpose, 15 ml aliquots
of the complexes samples (containing 0.375 mg of pDNA) were
subjected to electrophoresis on a 0.8% agarose gel containing
0.5 mg/ml ethidium bromide after mixing with 7 ml loading buffer
(0.25% bromophenol blue and 30% glycerol). Electrophoresis was
carried out in 80 V for about 2 h in 1X TBE running buffer. The
bands were observed with a transilluminator (Bio Doc-ITTM
System, UK). Images were captured using a digital camera.
DNase I protection assay. In order to assess protection
ability of cSLNs for loaded pDNAs, DNase I was added to cSLN–
pDNA complexes to a final concentration of 0.8 U DNase It o5mg
DNA and the mixtures were incubated at 37uC for 1 hr. Then
SDS solution was added to the samples to a final concentration of
1% to release DNA from cSLNs. Samples were then analyzed by
electrophoresis on agarose gel 0.8% containing ethidium bromide
and the integrity of the DNA in each sample was visualized and
compared with free DNA as control.
Vaccination studies
Mice, parasites and ethical considerations. The present
study was approved by ethical committee at Pasteur Institute of
cSLN-cps as a Vaccine Formulation against L. major
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maintenance and blood sample collections were taken under
supervision of animal care office of Pasteur Institute of Iran.
Female BALB/c mice, (6–8 weeks old, weighting 2065 g) were
obtained from the Pasteur Institute of Iran and were housed in
plastic cages with free access to tap water and standard rodent
pellets in an air-conditioned room under a constant 12:12 h light-
dark cycle at room temperature with relative humidity (50–60%).
The enhanced GFP gene (egfp) transfected L. major strain,
(MRHO/IR/75/ER) was kept in a virulent state by continuous
passage in BALB/c mice. A homogenized lymph node (LN) from
an infected BALB/c mouse was cultured in RPMI-1640 media
supplemented with 10% fetal calf serum and 100 mgo f
gentamycin/ml. Stationary phase promastigotes were harvested
by centrifugation at 3000 rpm for 10 min at 4uC. The pellet was
washed by PBS (8 mM Na2HPO4, 1.75 mM KH2PO4, 0.25 mM
KCl, 137 mM NaCl) and resuspended at a concentration of
3610
6 cells/ml. 50 ml of this preparation was injected subcutane-
ously in the left hind footpad (FP) of each mice.
Schedule of animal experiments. Seven groups, each
including 13 mice, were immunized in the right hind footpad
(FP), using an insulin syringe and a 29-gauge needle (Becton
Dickinson, NJ) in a total volume of 40–50 ml. The first group (G1)
was immunized with the cocktail of QiagenH purified pcDNA-cpa
and pcDNA-cpb (50 mg of each plasmid) formulated with cSLN
(named as Spa/b or cSLN-pcDNA-cpa/b). The second group (G2)
was immunized with the same amount of non formulated antigens,
dissolved in PBS (pcDNA-cpa/b). The third group (G3) was
immunized with the cocktail of QiagenH purified pcDNA-cpa and
pcDNA-cpb
-CTE (50 mg of each plasmid) formulated with cSLN
(named as Spa/b
-CTE or cSLN-pcDNA-cpa/b
-CTE). The forth
group (G4) was immunized with the same amount of non
formulated pDNAs, dissolved in PBS (pcDNA-cpa/b
-CTE).
Control groups received unloaded cSLN formulation (G5), the
pcDNA plasmid backbone (100 mg) formulated with cSLN (G6)
and PBS (G7). Three weeks later, the same regimens were
administered to all the groups, as booster immunization. The
vaccinated footpad of the animals was carefully observed for local
tolerance assessment at site of injection at 1 and 24 hr after
vaccine administration.
Mice were challenged 3 weeks after booster immunization as
metioned in the previous section and infection progress was
followed as described in the next sections. Blood samples were
t a k e nf r o mt h ee y ev e i no fe a c hi n d i v i d u a lm o u s eb e f o r ea n d9
weeks post challenge. The sera were pooled in each group and
kept at 220uC untilused. Prior to challenge, 3 mice form each
group (n=13) were sacrificed and their lymph nodes (LNs) were
existed and tested for IFN-c and IL-5 production. At the 9
th
week post challenge, 3 other mice from each group were
euthanized and their LNs were used for parasite burden
assesments via flow cytometry and microtitration methods and
cytokine profiling. The infected footpads of these mice (n=3)
were also dissected to be evaluated by flow cytometry technique
for parasite inhibition assessments. Four mice from each group
were randomely selected at this time (9
th week post challenge),
temporarily anesthetized and imaged for pixel counting and
measurement of the lesions asthe detailed procedures are
described in the next sections.
Flow-up of the disease progression
A- Footpad assessments. Determination of footpad
swelling: FP swelling was weekly monitored by measuring the
increase in thickness of the inoculated FP and the uninfected
contra lateral FP with a metric caliper.
Determination of the footpad parasitic load by flow
cytometry: Flow cytometry was used to quantify cells by
intracellular fluorescence as an indicator of Leishmania infection
and replication. Therefore to evaluate the relative efficacy of the
vaccination protocols, three mice from each group (n=10) were
euthanized at 9 weeks post challenge and the infected FPs were
homogenized with glass homogenizers in 3 ml of PBS under sterile
conditions. Normal non infected FP was also removed and
processed in the same manner as control. The recovered viable cell
suspension was washed with pre-cold PBS (pH 7.2), and
monitored using an Epi-fluorescence microscope (Nikon, E200,
Japan). Afterward, cells were directly applied to a Partec PASIII
flow cytometer (Partec GmbH, Germany) using a bivariate scatter
plot of fluorescence versus forward scatter, by gate setting with
uninfected FP cells. A minimum of 10,000 events from the viable
transfected cell population per sample were analyzed. Parasite
inhibition was measured in terms of the decrease in intensity of
green fluorescence in the FP of vaccinated animals. This was
calculated by comparing the intensity of fluorescence in vaccinated
and non vaccinated groups using following formula, (Eq. 1) [18].
Confidence interval with 95% (IC95%) was calculated for each
average of parasite inhibition percent considering the lowest and
highest values of fluorescent obtained from non vaccinated control
groups.
Parasite inhibition %~ 1{
Fluorescence of the vaccinated FP=LN
Mean fluorescence of the non vaccinated FP=LN

|100 ð1Þ
Detection of EGFP-transfected L. major in the foodpad of
BALB/c mice by imaging system: To demonstrate the in vivo
level of infection, the infected FPs of four mice per each group
(n=10) were imaged at 9
th week after challenge, with the
KODAK Image Station 4000 Digital Imaging System. Briefly,
all animals were treated with a depilatory substance (Nair) to
remove hair from their FPs to reduce background auto
fluorescence. Afterward mice were temporarily anesthetized with
the mixture of Xylazine 2% (7.5 ml), Ketamine 10% (30 ml) and
saline solution (260 ml) per mice intraperitoneally and then
imaged. Pixel counting and measurement of the lesions were
performed using KODAK molecular image software version 5.3.
Measurements were reported as ‘‘sum green intensity’’, a
quantitative measurement defined as the number of green pixels
in a given area multiplied by the average intensity of each pixel.
B-Parasite burden determination. Conventional
microtitration method: Three mice from each group (n=10)
were sacrificed 9 weeks after challenge and parasite burdens were
determined as follow: LNs were excised, weighed and then
homogenized with a tissue grinder in 2 ml of Schneider’s
Drosophila medium supplemented with 20% heat-inactivated
fetal calf serum and Gentamicin (0.1%). Under sterile conditions
serial dilutions ranging from 1 to 10
220 were prepared in 96 well
micro titration plates. After 7 and 15 days of incubation at 26uC,
plates were examined with an inverted microscope at a
magnification of 406. The presence or absence of motile
promastigotes was recorded in each well. The final titer was the
last dilution for which the well contained at least one parasite
[19,20]. Parasite burden and parasite inhibitions according to this
technique were calculated using Eq. (2) and (3). For this purpose,
parasite burden for each individual mouse was calculated
according to Eq. 2 and the mean values per each group were
used for calculation of the parasite inhibition percent according to
the Eq. 3. Same as Eq. 1, IC95% was calculated for each
vaccinated group, considering lower and higher fluorescence
cSLN-cps as a Vaccine Formulation against L. major
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Parasite burden~{log
Parasite dilution
Organ0s weight

ð2Þ
Parasite inhibition %~ 1{
Parasite burden of the vaccinated LN
Parasite burden of the non vaccinated LN

|100 ð3Þ
Determination of the lymph node parasite burden
directly by flow cytometry: Flow cytometry was used to
quantify the lymphatic cells by intracellular fluorescence.
Therefore, isolated draining LNs from individual mice (pool of 3
LNs) were homogenized into single cell suspensions using cell
dissociation sieves under sterile conditions. The tissue suspensions
were then centrifuged at 2806g for 5 min at 4uC to precipitate
most of the debris and to collect amastigotes in the supernatant.
LN of a non infected mouse as control was also removed and
processed in the same manner. The GFP-expressing amastigotes of
LN cells suspension was monitored using an Epi-fluorescence
microscope (Nikon, E200, and Japan). Afterward, cells were
directly applied to a Partec PASIII flow cytometer (Partec GmbH,
Germany) using a bivariate scatter plot of fluorescence versus
forward scatter, by gate setting with normal LN cells. A minimum
of 10,000 events from the viable transfected cell population per
sample were analyzed and percentage of their fluorescence
intensities were measured with respect to uninfected LN cells as
control. Parasite inhibition was measured in terms of the decrease
in expression of green fluorescence in the FP of vaccinated
animals, compare to the lowest and highest levels of this parameter
in the non-vaccinated control groups. PI% was calculated using
Eq. (1) and IC95% values were also determined for each average
of parasite inhibition of each group. This was calculated by
comparing the intensity of fluorescence in vaccinated and non
vaccinated groups using Eq. (1).
C-Cytokine assay. Prior to and 9 weeks post challenge, 3
mice form each group were sacrificed and LNs were existed,
homogenized and washed. LN cells were plated in triplicates in 96-
well microtiter plates in RPMI 5% (RPMI 1640 supplemented
with 5% FCS, 1% L-glutamine, 1% HEPES, 0.1% 2ME, 0.1%
gentamicine) as final count of 10
6 per well and stimulated with
10 mg of the corresponding recombinant proteins (rCPA, rCPB,
rCPB
-CTE), SLA (soluble Leishmania antigen) or Concanvalin A
(5 mg/ml, ConA), or culture medium (RPMI). Cell culture plates
were incubated for 5 days at 37uCi n5 %C O 2 humidified
atmosphere. Production of IFN-c and IL-5 were measured in
supernatant of stimulated LN cell culture by sandwich-based Elisa
kits (R&D, Minneapolis, MN, USA) according to manufacturer’s
instruction. The lower detection limits of IFN- c and IL-5 were 2
and 7 pg/ml, respectively. All tests were performed in triplicates.
D-Determination of antigen specific isotypes IgG1,
IgG2a. Pooled sera were prepared from each group of mice
before, and 9 weeks after challenge. Productions of IgG1 and
IgG2a antigen specific antibodies were measured against SLA,
rCPA, rCPB and rCPB
-CTE. Briefly 96 well plates were coated
with recombinant proteins or SLA antigen (10 mg/ml in PBS) and
incubated at 4uC overnight. After 3 washes with washing buffer
(PBS plus 0.05% tween20), plates were blocked with blocking
buffer (1% BSA in PBS) for 2 hours at 37uC and then, 100 mlo f
the pooled sera, diluted 1:50 in blocking buffer were added and
incubated for 2 hours at 37uC. Biotinylated anti mouse IgG1
(1:10000, Zymed, Burlington, ON, Canada) and IgG2a (1:500,
southern Biotech, Birmingham, USA) were added and incubated
for 2 h at 37uC. Streptavidine-horseradish peroxidase (BRL,
Gaithersburg, MD) was added (1:1000) and incubated for 1 h at
37uC. Conjugates’ binding were visualized with OPD (complete
name) and the reaction was stopped by sulfuric acid (4N) and the
absorbance was measured at 492 nm.
Statistics
Statistics were performed using Graph-Pad Prism 5.0 for
Windows (Graphpad Software Inc 2007, San Diego, Calif., USA).
All the data analyzed with one way ANOVA (Multiple
comparisons Tukey post test) when required, with the exception
of size and zeta potential measurements, which were analyzed with
a Student’s t-test. A p-value of #0.05 was considered as significant
difference between the groups. ‘‘n’’ represents number of mice per
group or samples per assay.
Results
Physicochemical characteristics and in vitro evaluations
of the vaccine formulation revealed the potential
effectiveness of cationic SLN for pDNA delivery
cSLN were produced by using the modified microemulsion and
high shear homogenization method, cetyl palmitate and choles-
terol as matrix lipid, DOTAP as charge carrier and Tween 80 as
surfactant. Obtained nanoparticles were approximately
257623 nm in size and positively charged with a zeta potential
of +5268 mV in milli Q water and size distribution of 0.3460.08.
This suspension was stable for 30 days (p,0.05). The SLN-pcDNA
stable complexes (Spa, Spb and Spb
-CTE) were prepared by pDNA
adsorption on the surface of cSLNs via direct complexation with
pcDNA-cpa, pcDNA-cpb and pcDNA- cpb
-CTE, respectively. These
formulations were also characterized according to their size, zeta
potential and poly dispersity index (PDI, Table 1). The results
indicated that Spa, Spb and Spb
-CTE cationic formulations had an
average size of 244612, 250615 and 237612 nm, respectively.
There was no significant difference in the size of different
preparations (p.0.05). Spa, Spb and Spb
-CTE had a mono disperse
formulation as the PDI value was about 0.2 for all of them. The
observed zeta potential revealed all the formulations were cationic
(f potential=22 to 27 mV) that is suitable for interaction with the
negatively charged cell surface and the cell entry.
The agarose gel electrophoresis analysis was used to test Spa,
Spb and Spb
-CTE formulations for their ability to condense pDNA
through electrostatic interactions after preparation (data not
shown). Gel retardation assay for SLN-pDNAs confirmed
complete complexation between pDNA and cSLN at a DO-
TAP:pDNA ratio of 6:1. Cationic SLN were able to protect pDNA
against DNase I digestion as previously reported [17]. Spa, Spb and
Spb
-CTE formulations were stable at refrigerated temperature
Table 1. cSLN formulations and their characteristics.
Formulation Size (nm) Zeta potential (mV) PDI
cSLN 257623 +5268 0.326
Spa2 4 4 612 +2763 0.254
Spb2 5 0 615 +2263 0.264
Spb
-CTE 240612 +2567 0.283
Nanoparticles were formulated from cetyl palmitate, cholesterol and DOTAP
hydrochloride. Results represent mean6SD of three independent SLN
preparations.
doi:10.1371/journal.pntd.0001236.t001
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cSLN formulations was 0.215 EU/50 ug.In our previous in vitro
studies on COS-7 cells, we demonstrated a very low degree of
toxicity of both cSLN and cSLN–pDNA complexes. Furthermore,
flow cytometry analysis confirmed SLN-pDNA complexes were
able to promote transfection of COS-7 cells at least for 72 hrs after
treatment of these cells without a significant reduction in cell
viability and in vitro CPs expression capacity [17].
Disease progression monitoring by five different
techniques revealed the efficacy of Spa/b
-CTE cocktail
DNA vaccination
The efficacy of cocktail pDNA vaccines containing pDNAs
encoding CPA/CPB, CPA/CPB
-CTE, and the same cocktail
pDNA vaccines formulated with cSLN (Spa/b and Spa/b
-CTE)
were evaluated by their capability to induce protection against
Leishmania infection in the BALB/c mice model. It is worth to
mentin that, no apparent sign of local intolerance such as redness,
swelling, bruising, pain observed at the site of injection 1 and
24 hr after vaccine administration. Parasite inhibition in different
groups was assessed on both FP and LN of animals. For this
purpose, dynamic measurement with a metric caliper, parasite
load determination by flowcytometry and imaging techniques
were done on the infected mice FP. In parallel, the parasite load
was assessed in the LN via microtitration and flowcytometry
methods.
As shown in Figure 1, FP swelling of seven different groups of
micen=10)was measured after a challenge inoculationwith EGFP-
transfected stationary phase promastigotes of L. major. All the mice
which have received the empty cSLNs (G5), pDNA vector without
any insert formulated with cSLN (G6) or PBS (G7); showed
significant lesions by 7 weeks post-challenge. There was a significant
(p,0.05) difference between animals received formulation Spa/b
and Spa/b
-CTE (G1 and 3) and animals immunized with non-
formulated cocktail vaccines (G2 and 4) at 9
th week post challenge.
The latter groups did not show any significant difference with the
control groups. There was also a significant (p,0.05 difference
between group 1 and 3, confirming that the higher level of
protection observed in group 3. However, this difference between
the cocktail vaccine compositions was not significant in group 2 and
4 and this difference could not be simply described due to the
presence of CTE in the texture of the Spa/b cocktail vaccine. It
seems that utilizing cSLNs for the formulation of pDNAs could
potentiate the manifestation of this difference between the vaccine
compositions. Vaccination with cSLN-pDNA encoding cpa, cpb (G
1) or cSLN-pDNA encoding cpa, cpb
-CTE (G3) delayed FP swelling
when compared to immunization with cSLN and PBS (G5 and 7),
at this time point. For a certain time, immunization with the
pcDNA-cpa/b and pcDNA-cpa/b
-CTE cocktail vaccines had a
significant effect in delaying FP swelling. However, this effect was
not long lasting and 9 weeks after challenge, there was a significant
difference (p,0.05) in protective effect between groups 3 and all of
the other groups including group 1. Furthermore, the mean FP
lesion size in group 1, was still significantly (p,0.05) lower than that
in the control groups. Totally, vaccination with a cocktail of cpa, cpb
-
CTE formulated with cSLNs (G3) resulted in control of the infection
progress compare to the control groups as all of the animals in this
group developed significantly smaller FP lesions (2.0260.7 mm) at
9
th week after challenge.
Figure 1. Assessement of footpad swelling in vaccinated mice. Schematic presentation of the mean footpad measurements via caliper based
method in mm (left axis) with standard error over the course of the Leishmania infection following pcDNA-cps immunization. BALB/c mice, thirteen
animals in each group, were immunized subcutaneously with cSLN-pcDNA-cpa/cpb (G 1); pcDNA-cpa/cpb (G 2); cSLN-pcDNA-cpa/cpb
-CTE (G 3),
pcDNA-cpa/cpb
-CTE (G 4); cSLN (G 5), cSLN-pcDNA (G 6) and PBS (G 7). Mice were immunized again 3 weeks later with the same schedule. Three weeks
after the booster immunization, mice were challenged in the left footpad with L. major 5days stationary phase promastigotes (3610
6 cells/mouse).
Weekly measurements of footpad thickness represent the mean score 6 SD in each group (n=10). From the 9
th week, a statistically significant
difference (*p,0.05) was seen between G3 and the control groups. This difference continued up to the end of study course. (‘‘G’’represents ‘‘group’’
in all the graphs).
doi:10.1371/journal.pntd.0001236.g001
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experiment at 9
th week post challenge, we also detected EGFP-
expressing L. major in the FPs of mice using fluorescence imaging
system that is supposed to give a precise two-dimensional image
from the extent of infection, independent of the inflammatory
responses at the FP injection site. This experiment enabled us to
clearly detect the parasite load in the infected FPs (Fig. 2). As
shown in this Figure, the GFP fluorescence in the control group of
animals was not localized to the site of the inoculation and the
parasites spread to the whole FP. We also observed that the
increasing thickness of the infected FPs was not correlated with the
intensity enhancement of the detected GFPs in the tested animals
(Fig. 2). The sum green intensity (pixel) from the imaging studies
were higher in infected FP of the control groups. Furthermore,
only group 3 of the tested animals revealed significantly (p,0.05,
n=4) lower GFP intensity compare to the other groups (Fig. 2).
EGFP expression in L. major amastigotes resident in the FPs was
also monitored by flow cytometry technique. High expression
levels of EGFP were observed in PBS treated group (G 7, Fig. 3).
Fluorescence activated cell sorting (FACS) analysis indicated a
clear quantitative separation between parasite transfected and
normal cells. The frequency of EGFP positive cells of the FPs
determined by FACS analysis using the appropriate gating are
shown in Fig. 3. Group 3 of the vaccinated animals had the lowest
infection rate (12.77%60.62) compare to the other groups. The
percentages of GFP-expressing parasites were significantly lower in
the FP cells of the group 1 and 3 of the vaccinated animals.
The infection progression was also followed by determining the
total parasite load in the LNs of challenged mice at 9 weeks post-
infection by the microtitration method (Fig. 4A) and flowcyto-
metry (Fig. 4B). According to microtitration method and compare
to control groups, parasite load in the LNs of vaccinated groups
with Spa/b
-CTE (G3) decreased significantly (p,0.05, n=3)
(Fig. 4A). The expression of EGFP in the LNs was readily evident
from the intense green fluorescence of the parasites (Fig. 4B). The
parasites reside inside the LN cells were quantified by monitoring
EGFP expression via flowcytometry analysis. As shown in Fig. 4B,
Group 1 and 3 both expressed significantly (p,0.05, n=3) lower
percent of EGFP that is correlated with the least amastigote
parasite existence in the lymphatic cells. On the other hand,
parasite burden in the group 3 was significantly (p,0.05) lower
than group 1.
It is noteworthy that, the rate of infection in all groups was in
concordance with the delay in the appearance of lesions, the
thickening peaked at 9 weeks post-infection and the parasite load
in the LNs and FPs determined by microtitration, flow cytometry
and imaging methods. Mice vaccinated with formulated cocktail
plasmids i.e. Spa/b and Spa/b
-CTE (G1 and G3) showed a
significant decrease in the FP tissues parasite load as well as LN,
compared to the control groups. The ability of the vaccines to
inhibit the infection progress and parasite replication [parasite
inhibition (PI) %] was predicted according to the assessment of the
FPs and LNs parasite load via imaging and flow cytometric
method in terms of the decrease in intensity of green fluorescence
observed in vaccinated animals, as well as parasite burden of the
FPs and LNs by flowctometry and microtitration method. As
shown in Table 2, the given rates were calculated by comparing
the precentage of fluorescence intensity or parasite burden in FPs
and LNs of vaccinated mice to the lowest and highest intensity of
fluorescence in the non vaccinated groups. Average of PI% rates
were more expressive, when FP imaging and LN flow cytometric
techniques were used. The average PI% in G3 was significantly
higher than other vaccinated groups when determined by different
methods, executed on FPs and LNs. The mean average of parasite
reduction in this group was 87.11% (IC95%, 85.9–88.33) by FP
imaging, 65.64% (IC95%, 61.29–69.98) by FP flow cytometry,
Figure 2. Fluorescence imaging of the footpads. Fluorescence imaging was performed at 9
th week after challenge Four mice from each group
were selected randomly for this experiment, but one representative mouse of each group was chosen for the photographs, taken by fluorescence
imaging system. Footpads from each group were averaged for each data point to demonstrate sum green pixel count in the fluorescence image at
this time point. The mean of the sum green pixel count with standard error from footpad images plotted for each group. The vaccinated mice in
group 3 showed significantly (*p,0.05, n=4) lower footpad size and sum green pixel count from the other groups.
doi:10.1371/journal.pntd.0001236.g002
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(IC95%, 87.78–85.75) by LN flow cytometry (Table 2). The
profile of the alteration in the PI% results in all of the vaccinated
groups were correlated with the results of the LN parasite burden
via microtitration assay and footpad swelling. Neither imaging nor
flow cytometry assays could discriminate between the parasite
inhibition results of G1 and G3 of the vaccinated animals, when
manipulating the animals’ footpads (Table 2).
Cocktail DNA vaccination with Spa/b
-CTE formulation
encoding CPA, CPB
-CTE enhanced the IFN-c production
In order to compare the induced immune responses by different
DNA cocktail vaccination strategies and explore the protective
effects against L. major challenge in BALB/c mice, IFN- c and IL-5
production were assessed after in vitro stimulation of LN cells with
both Leishmania soluble antigen (SLA) and recombinant CPs, pre
and post challenge. According to IFN-c production, pooled cells
from three mice of groups 1, 2, 3 produced significantly (p,0.05)
higher levels compared to control groups before infection in
response to the rCPs (Fig 5A). Although group 3 produced higher
amounts of IFN-c (522.98611.99 pg/ml), but was not significant-
ly higher than the other vaccinated groups. Low IFN-c production
was detected in supernatants of LN cells of all three control groups
in response to rCPs, before challenge. At 9
th weeks post challenge,
the rprotein specific IFN-c production level increased only in
group 1 and 3 of the animal vaccinated with Spa/b and Spa/b
-CTE
formulations, respectively. Although, the difference in IFN-c
production level was only significant (p,0.05), in group 3
(773.29616.78 pg/ml) of animals compared to control groups
(Fig. 5B). No IL-5 was detectable in the supernatant of cells from
all groups after stimulation with rCPs before challenge (data not
shown). In contrast, significant levels of IL-5 were detected in the
supernatant of cells from group 5, 6 and 7, in response to rCPs
SLA at 9
th week after infection, compared to all the vaccinated
groups of animals (G1, 2, 3 and 4, Fig. 5C). There were no
significatnt difference in Con A-induced cytokine production,
among the tested groups.
Further analysis of the induced cytokines profile by means of
IFN-c/IL-5 ratio revealed that only formulated cocktail DNA
vaccines (Spa/b and Spa/b
-CTE) could clearly induced strong Th1
immune responses (Fig. 6). As shown in this Figure, this ratio was
significantly (p,0.05) higher in group 3 of vaccinated mice
compared to the other groups suggesting a higher level of
protective immunity.
CP-specific production of IgG2a correlated with
protective effect of cocktail DNA vaccination with
Spa/b
-CTE
To compare IgG isotypes in protected and non protected
vaccinated groups, sera were collected before and 9 weeks after
challenge and assessed for IgG1 and IgG2a. To determine the
antibody specificity, all sera of vaccinated and control mice were
Figure 3. Flowcytometry analysis of the footpads. The bars represent the average percentage of GFP positive footpad cells 6 SD of three mice
per each group GFP fluorescence expression was significantly lower in the footpads of group 3 (*p,0.05).
doi:10.1371/journal.pntd.0001236.g003
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26uC in serial 10-fold dilution. The wells were assessed microscopically for L. major growth, and the number of viable parasites was determined from
cSLN-cps as a Vaccine Formulation against L. major
www.plosntds.org 9 July 2011 | Volume 5 | Issue 7 | e1236pooled and assayed by ELISA method before (Fig. 7A, B and C)
and after (Fig. 7D, E and F) challenge with L. major promastigotes.
As it is shown in these Figures, the group of mice that developed
an effective protective response (e.g., group 3) had substantially
higher levels of CPA-specific IgG2a antibody compared to
unprotected mice, both before (n=13) and after (n=10) challenge
(Fig. 7A, C). This is consistent with the results obtained above that
SLN formulated cocktail DNA vaccine encoding cpa and cpb
-CTE
(Spa/b
-CTE) preferentially induced a Th1 response. According to
the Fig. 7D, higher levels of CPB-specific IgG2a was produced in
G1 and 2 of the vaccinated mice. This might be described by the
immunogenic nature of CTE fragment. The productions of IgG1
in the control groups were significantly higher than IgG2a after
challenge, when stimulated by SLA (Fig. 7E).The ratio of IgG2a/
IgG1 in sera of mice immunized with Spa/b
-CTE formulation was
higher than the other groups when titrated against rCPA (Fig. 8).
This ratio was also higher in sera of mice immunized with the
pcDNA-cpa/b
CTE formulation than all the other vaccinated
groups.
Challenged with GFP expressing L. major promastigotes induced
high level of IgG1 antibody titers against SLA in all groups
(Fig. 7E). The sera of mice immunized with Spa/b
-CTE
formulation showed higher levels of specific IgG2a antibody
compared to the IgG1, when titrated against SLA and higher
IgG2a/IgG1 ratio was only observed in this group of vaccinated
animals.
Discussion
Although vaccination in the endemic populations is the most
cost-effective tool to diminish the burden of Leishmaniasis,a n
effective vaccine to control this disease is not commercially
available yet [2]. It is unlikely that an effective anti-Leishmania
vaccine based on the use of a single antigen will be achieved. This
might be due to the complex and biphasic life cycle of Leishmania
parasite. Therefore, a rational approach toward developing an
effective cocktail vaccine should be the use of extracellular and
intracellular parasite antigens resulting in a valuable cumulative
immune response [3,14]. In this regard, ease of combining
different pDNA vaccine candidates has made genetic vaccination
an attractive platform for vaccination strategies [3,4].
However in most cases, even multivalent or cocktail DNA
vaccines have failed to achieve the required level of protection
possibly due to the lack of an appropriate delivery system and/or
adjuvant [3,16]. Therefore, there is still an urgent need for
development of new, safe and improved adjuvant and/or delivery
systems to enhance the immunogenicity of the available vaccine
candidates. There are versatile conflicting reports about DNA
vaccination effectiveness against leishmaniasis. Most of DNA
vaccine candidates have been tested as single vaccine regimens,
but there are also some reports about using combination of genes
[1,3]. Up to date despite of the heterogeneity of vaccination
protocols, mean average of parasite load reduction was deter-
mined to be 59.24% (IC95%, 47.75–70.73) [3]. This might be due
to the reason that adjuvants and delivery systems were rarely
added to the formulations containing candidates of the mentioned
third-generation vaccines [3]. Approved adjuvants for human
vaccines are poor inducers of antigen-specific Th1 responses that
are necessary for an intra cellular parasite like Leishmania [21].
Therefore, several strategies, including live vectors; saponins;
Freund’s and montanide ISA 720 water-in-oil emulsions; oil-in-
water emulsions (MF59); dendritic cells (DC) and liposomes have
been utilized in different studies and trials to deliver antigens and
redirect the immune responses towards desired Th1 pathway [22].
However, most of these failed to provide both long-term immunity
and safety for human vaccines.
Therefore, it is still crucial to develop a potentiated delivery
system with Th1 stimulating, safe and cost-effective properties for
such a promising vaccination technology. Nanoscale vehicles are
able to boost the quality and magnitude of an immune response in
a predictable, designable trend that can be applied for wide-spread
use of genetic vaccination, for developing vaccines for diseases
Table 2. Average parasite inhibition percent (PI%) by different methods.
Determination
Method Average Parasite Inhibition (%)
Effective
formulation(s)
Discrepancy between Effective formulations
(*p,0.05)
G1 G2 G3 G4 G1vsG2 G1vsG3 G2vsG4 G3vsG4
FP Caliper based
measurement (Fig. 1)
Not applicable Spa/b
Spa/b
-CTE
**N S *
FP imaging
(Fig. 2)
77.7265.78 47.5966.99 87.1161.72 54.7166.04 Spa/b
Spa/b
-CTE
*N S N S *
FP flowcytometry
(Fig. 3)
51.668.6 25.35613.3 65.6466.15 39.42610.84 Spa/b
-CTE *N S N S *
LN microtitration
(Fig. 4A)
36.2869.8 24.17611.68 41.4369.02 28.51611.02 Spa/b
-CTE **N S *
LN flowcytometry
(Fig. 4B)
66.8268.2 41.35614.4 86.7761.4 50.37612.23 Spa/b
Spa/b
-CTE
**N S *
Average PI% measured in terms of the parasitic load decrease in the footpad (FP) and/or lymph node (LN) of vaccinated animals compared to the control groups via
different methods. (‘‘NS’’ represent as ‘‘not significant’’ and ‘‘*’’ represents significant difference between the mentioned groups).
doi:10.1371/journal.pntd.0001236.t002
the well with the highest dilution. The bar represents the average score6SD of three mice per group. Results are representative of at least two
independent experiments and revealed a significant (*p,0.05) decrease in G1, G3 of the vaccinated mice compared to the control groups. (B)
flowcytometry analysis. 9 weeks post-infection, intracellular fluoresence of the lymph node cells (pool of lymph nodes of three mice from each group)
was quantified by Partec PASIII flow cytometer. ‘‘*’’ reveals significantly decrease in group 1 and 3 compared to unvaccinated control groups
(p,0.05).
doi:10.1371/journal.pntd.0001236.g004
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through relatively ineffectual therapeutic regimens. Nanoparticles
as vaccine delivery systems, promote bioactive vaccine candidate
protection against extracellular degradation and modulate cellular
and humoral immune responses via targeting antigens to APCs
such as DCs and therefore would be potentially useful as effective
vaccine adjuvants [15]. Cationic lipid-based systems could be
formulated as emulsions, liposomes or cationic solid lipid
nanoparticles (cSLN). These Lipid-based delivery systems are able
to protect the nucleic acid payload and significantly reduce its
degradation and extend its activity, improve the pDNA pharma-
cokinetic characteristics and thus induce more potent immune
responses due to a depot effect in which persistence of pDNA at
the site of delivery allows uptake by local immune cells, enhance
intracellular uptake and delivery to target APCs [15]. Amongst
these, SLNs have offered a number of technicopractical advan-
tages including proper storage stability, easy production proce-
dure, steam sterilization and lyophilization possibility and
acceptable safety profile [7,8]. In regards to vaccination studies,
significant enhancement was reported when using cSLN-pDNA
formulation for cholera toxin and lipid A delivery so that well
tolerated particles with sizes greater than 100 nm exhibited higher
adjuvant activity enhancing both T-helper types of immune
responses compared to the FIA [8]. Hence, in this study we
considered SLN for formulating cpa and cpb or cpb
-CTE genes. In
our previous study, these genes as DNA prime boost vaccination
regimen have induced partial protective responses in susceptible
BALB/c mice [14]. Heterologous prim-boost immunization
approaches have complex logistics and high costs associated with
manufacturing a second vaccine platform. Therefore, utilizing a
suitable delivery system might be an important strategy to
eliminate the need for boosting with the recombinant proteins
and enhance third generation vaccine’s potency by preventing
rapid elimination of the administered pDNA from the circulation.
In this regard, cSLN formulations were prepared and character-
ized regarding their size, zeta potential, nuclease protection, in vitro
transfection efficiency, and cell viability, in our earlier report [17].
To assess the cSLN utility prospect as a leishmanial vaccine
delivery system, we exploited GFP-transfected Leishmania for
generating experimental cutaneous leishmaniasis in BALB/c mice.
This model was reported as a novel dynamic immunopathogenic
tool allowing visualization and correlation of fluorescence intensity
with parasite burden [23,24]. Some concerns might be raised
according to an anti-GFP immune response which could be
induced against expressed GFP by the parasites. Several studies
indicated that no immune responses have been detected in animals
immunized with recombinant EGFP. In other words, recombinant
EGFP is not able to stimulate APCs, nor do it induce a significant
T-cell response or anti-EGFP antibody production [25]. In our
investigations for precise judgment about the feasibility of this
delivery system, we looked for a more rapid, sensitive and easily
reproducible method to predict average parasite inhibition (PI) in
Figure 6. The ratio of IFN-c/IL-5 production. The ratio presentation at week 9
th after challenge in the lymph node cells stimulated by SLA and
respective rCPs. This ratio was significantly (*p,0.05) higher in the animals immunized with Spa/b
-CTE (G3).
doi:10.1371/journal.pntd.0001236.g006
Figure 5. Cytokine production by lymph node (LN) cells from L. major-infected mice. Single-cell suspensions were prepared from the LN of
three mice in the designated groups, before (n=13) and 9 weeks after infection (n=10). Cells cultured in triplicate for 5 days in the presence of
recombinant antigens (10 mg/ml), soluble Leishmania antigen (SLA, 4 mg/well), Con A (as positive control) and RPMI (as negative control). Culture
supernatants were assayed for levels of IFN-c, before challenge (A), after challenge (B) and IL-5 (C) production by ELISA. There were no difference in
Con A-induced cytokine production, among the groups. Each bar represents the mean 6 SD for three mice per group (n=3). Results are
representative of two independent experiments, each performed in triplicate.
doi:10.1371/journal.pntd.0001236.g005
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techniques were used in this regards and the outcomes were
correlated to the conventional standard caliper-based method
and microtitration parasite burden as well as cytokine and
antibody responses to choose the most sensitive, precise and less
time-consuming technique for following Leishmania infection, in
mice model. As illustrated in Table 2, to evaluate the protection
rate; FP swelling (Fig. 1), imaging (Fig. 2) and flowcytometric
analysis on the FP (Fig. 3) and LN (Fig. 4B) were assessed in
immunized mice and the results were compared to each other
and the control groups. The LN parasite burden was also
determined by microtitration conventional method (Fig. 4A), at
the same time point. The results demonstrated that the size of
lesion in mice immunized with Spa/b and Spa/b
-CTE at week 9
post challenge were significantly (p,0.05) smaller compared to
control groups. Interestingly, the mice immunized with cpa/cpb
and cpa/cpb
-CTE had also revealed significant difference in FP
swelling compared with the group of mice immunized with the
formulated cocktail of pDNA-cps (p,0.05). However, there was
no significant difference between the groups of mice received
non-formulated cocktail vaccines. The same results were
obtained through LN analysis by microtitration and flowcyto-
metry. The mentioned methods disclosed the significant PI
discrepancy between Spa/b and Spa/b
-CTE formulations, while
FP analysis couldn’t discriminate the effective vaccination
strategy between these formulations. However, although FP
caliper and LN microtitration based procedures were accurate,
precise and capable of differentiation between effective formu-
lations in terms of tissue prasitism, they were time-consuming,
rather difficult and not absolutely reproducible as the risk of
operator errors are more probable in these experiments.
Therefore according to the presented data, it seems that
parasite inhibition can be directly estimated by flowcytometry
analysis performed on LN cells; as a more rapid, sensitive, and
easily reproducible method for screening anti Leishmania vaccine
candidates and delivery systems.
Figure 7. Antigen-specific IgG1 and IgG2a responses. Before and at week 9
th after challenge, blood samples were collected and pooled sera
(diluted 1:50) per each group was prepared. Antibody responses stimulated by rCPA (A, C) and rCPB or rCPB
-CTE (B, D) and SLA (E) showed the profile
of CP-specific antibodies, induced before (n=13) and after (n=10) challenge. The data represent means6SD. Results are representative of two
independent experiments, each performed in triplicate.
doi:10.1371/journal.pntd.0001236.g007
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of vaccinated groups of mice after challenge and compared to the
control groups, and used as an indication of the protection rate or
average parasite inhibition percent (PI%). The significantly
(p,0.05) higher mean PI% was seen in group 3 (73.36615.94%)
which was immunized with Spa/b
-CTE formulation. This result
further revealed the adjuvant effect of the cSLN for potentiating the
immunogenicity of this genetic vaccination strategy (Fig. 1, 2, 3,
4A and B) and (Table 2). It seems that a/b
-CTE cocktail vaccine
induced lower levels of the protection and needs a suitable delivery
system to maintain and enhance its immunoprotective activity
(44.38612.59%). This obtained protection rate is in accordance
with the percents of reduction of parasite load, reported to obtain
with DNA vaccination, without a booster injection (59.24%) [3].
However, despite using cSLN, Spa/b formulation couldn’t provoke
the same PI%. as did Spa/b
-CTE (58.31617.61%). This difference
could bebetterdescribedbytheantigenicnatureofthe pDNAsused
in this experiment and further confirms our previous results that
CTE is highly immunogenic but not protective and more favorable
to direct the immune system responces towards Th2 type. Based on
the presented data, cSLN formulation conferred immunoprotecting
activity to a/b
-CTE genes which were non-immunoprotecting in
their free form, and possibly enhance the immunostimulatory
activity of these genes, by effectively inducing TLR-9 mobilization
in the endosomal compartment. According to the data presented in
Table 2, despite utilizing highly sensitive methods to determine
parasite burden, there was no significant difference between cpa/cpb
and cpa/cpb
-CTE cocktail DNA vaccines (G2 vs G4; Table 2). On the
other hand, the discrepancy between these cocktails was significant
when they were formulated with cSLN and the parasite burden was
determined by LN manipulation (G1 vs G3, Table 2). This data
further supports the importance of the lymph nodes as one of the
most relevant tissues involved in the parasite-host interface during
the stages of L. major infection as the cellular and humoral immune
responses in the LN are able to better describe the major
immunological changes due to parasite persistence during infection.
Therefore, LN may reflect the profile of the host’s immune response
and the parasite burden intensity throughout L. major infection via
both conventional (microtitration) and novel (flow cytometry)
techniques. PI% were singnificantly different between the groups
received formulated and nonformulated cocktail vaccines(G1vs G2
and G3 vs G4). These results emphasis induction of the immune
responses by using delivery systems in such an extent that even the
effect CTE deletion could be detectable in the disease progression.
To further evaluate the precision of the obtained data, the
cytokines produced by antigen-specific T-cells, were evaluated to
determine the profile of an elicited antibody response. IL-5 is
associated with high levels of IgG1, whereas production of IgG2a
is dependent on IFN-c. Our results demonstrated that the immune
response elicited by Spa/b and Spa/b
-CTE formulations was
dominantly Th1 response denoted by the higher ratio of IFN-c/
IL-5 secretion after stimulation with SLA and rCPs. However this
ratio was significantly higher in Spa/b
-CTE vaccinated animals.
This ratio is approximately 3-fold higher when SLN has been used
as a delivery system. T-cell immunogenicity of CPs had been
shown in previous studies, where immunizations with L. mexicana
Figure 8. The ratio of IgG2a/IgG2a production. The ratio presentation at 9
th week after challenge in the different groups determined against
rCPA. This ratio was significantly (*p,0.05) higher in the animals immunized with Spa/b
-CTE (G3).
doi:10.1371/journal.pntd.0001236.g008
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protective Th1 cell line, and that recombinant CPB from L. major
efficiently induced CD8+ T-cells [9,26]. Therefore, SLN proceed-
ed as a Th1 stimulator adjuvant and increased the cocktail vaccine
efficiency in elicitation of protective responses.
IgG1 and IgG2a antibody titers were also used as an indicator of
Th2 and Th1 immune responses, respectively. The significantly
(p,0.05) highest IgG2a was seen in the sera of group 3 of mice
immunized with Spa/b
-CTE before challenge against recombinant
CPA compared to other groups. This might be an indication that
CTE-domain deletion in Spa/b
-CTE formulation redirected the
immune responses toward increasing IgG2a production. However,
using cSLN formulation for this cocktail vaccine consequently
induced a more potent antibody response compared with free
pDNAs (Fig. 7A, C and G3, G4). At week 9
th after challenge, the
IgG2a/IgG1 ratio in mice vaccinated with Spa/b
-CTE formulation
(G3) was correlated with a Th1 response and further confirmed that
could induce a potent Th1 type of immune response and protection
against leishmaniasis, at least in murine model. Only G3 showed
significantly (p,0.05) highest ratio of IgG2a/IgG1, revealing the
induced protection in this group confirmed by a significant smaller
FP swelling (p,0.05), lower LN parasite load (p,0.05),highest IFN-
c/IL-5 ratio (p,0.05) and maximum average of parasitic inhibition
percent by flowcytometry and imaging methods.
Despite, using cSLN as a delivery system, the immune responses
to the selected antigens (cpb and cpb
-CTE) of the cocktail vaccine
were differed. Generally, the titres of specific antibodies raised by
DNA vaccination are lower than those obtained after vaccination
with a recombinant protein. As it is shown in this study antibodies
are induced to a very low extent against CPB
-CTE, especially in
comparison to antibody levels against CPB (Fig. 7B, D). This is
definitely attributed to the presence of immunogenic CTE-domain
in the vaccine formulations administered to G1 and G2 that affect
the character and potency of the responses against defined
antigens in the mentioned cocktail vaccines. As a part of our
experiments, we have performed an ELISA test in which pooled
sera of G1 and G2 were tested against CPB
-CTE and sera of G3,
G4 tested against recombinant CPB. As a result, G1 and G2
revealed reduced antibody responses while G3, G4 did not show
any difference in antibody responses (data not shown). Thus,
to avoid presenting exaggerated responses in the benefit for
Spa/b
-CTE formulation, the presented data show the results of the
experiment in which each group plated against its own set of
antigens. Therefore, CTE-domain deletion is shown to be an
appropriate approach to design a protective vaccine candidate
against L. major as well as L. infantum infectious challenge [13].
Above mentioned protective Th1 response demonstrated in G3
that was characterized by increased titres of IgG2a in sera and
elevated IFN-c production by LN cells both before and after
challenge, was further supported by the report by Brewer J M et al.
indicated that lipid vesicles with a mean diameter .225 nm
preferentially induces Th1 responses in BALB/c mice [27]. On the
other hand, pcDNA-cps also possesses several immunostimulatory
CpG motifs within pcDNA3.1 vector backbone. These CpG
motifs might also facilitate priming of CTL responses by activating
DCs [28]. Nevertheless, this effect is often temporary because of
the rapid degradation of DNA [5,15] and consequently repeated
administrations or much higher doses are required to achieve the
desired effects. Moreover, the pDNA delivery to the intracellular
compartments for recognition by TLR-9 is hardened [5,29]
without a delivery system, as shown for G2 and G4. Therefore, we
can conclude that cSLN as a delivery systems improved the
storage stability [17], transfection efficiency [17] and immunosti-
mulatory effects of pDNA-cps (Table 2).
This was possibly the result of pDNAs protection from nuclease
activity in vivo, as we have previously reported this potential in vitro
[17] and facilitation of pDNAs delivery to the cytoplasm because of
cSLN positive zeta potential and the presence of cholesterol
domains in cSLN formulation that enhances transfection efficiency
by facilitating membrane fusion [17,30]. In addition, phagocytosis
of cSLN-pDNAs by APCs as well as localization of them in the
draining LNs occurs easily following SC administration due to the
composition and physicochemical characterization of these nano-
particles. The presence of Tween 80 in the formulation enhances
this phenomenon as recently Seeballuck and co-workers have also
demonstrated that, this surfactant would increase lymphatic uptake
by promoting chylomicron formation [31]. Since the draining LNs
contain a greater number of cells that express TLR9, localization of
pDNAs in the draining LNs possibly will be an important
mechanism by which cSLN formulation has enhanced the
immunological activity of these antigens. Another important aspect
in this formulation could be the presence of DOTAP in this cSLN
formulation that can also activate the dendritic cells through a
common binding partner with LPS [32]. Therefore, this formula-
tion not only act as a delivery system but also as an adjuvant for
Leishmania vaccine by improving the uptake of loaded antigens and
also stimulating immune cells in specific way.
In conclusion, this paper clearly demonstrates that cSLN is a
promising and adaptable delivery system that can be modified
rationally towards specific vaccine targets by varying composition.
Simplicity, reproducibility and the scale up possibility of the
manufacturing process together with the appropriate immunosti-
mulatory effects of this formulation as a delivery system might be
utilized to create a stronger protective vaccine in combination with
Leishmania CPs. The current data, in murine model of L. major
infection,showedpromisingrole ofcSLNasanadjuvant toenhance
stronger immune response against Leishmania infection. The mean
average of parasite load reduction for such a cocktail pDNA
vaccination was determined to be 38% [1]. Here in this study, we
reportthatthepercent ofparasiteinhibitionbyaparticulatecocktail
DNA vaccination technology could be increased up to
73.36615.95%, according to the precise methods for parasite
burden determination in the different organs of the challenged
animalsvia both conventional(i.e. microtitration,Fig.4A)andmore
novel(i.e.flowcytometry,Fig.3,4Bandimaging,Fig.2)techniques.
In the entire mentioned techniques parasite burden gave a
discriminative view among control groups and Spb
-CTE vaccinated
animals. Amongst the disscussed methods, direct LN flowcytometry
was found to be the most rapid, sensitive, and easily reproducible
method for screening vaccination strategies. These promising data
warrant further investigations in this regard. Our future studies are
being designed to expand cSLN passive targeting to an active
targeting to increase the vaccination efficiency. Coating cSLN
harbouring pDNA-cps with ligands (such as mannan) are our main
future visions to increase the cellular immune responses.
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